Differential Effects of Ticagrelor With or Without Aspirin on Platelet Reactivity and Coagulation Activation: A Randomized Trial in Healthy Volunteers

Figures

• 

  Figure 1. Boxplots of the effects of ticagrelor combined with aspirin and ticagrelor combined with placebo on adenosine diphosphate‐triggered platelet aggregation (multiple electrode aggregometry (MEA)‐ADP) (a), arachidonic acid‐triggered aggregation (MEA‐AA) (b), and vasodilator‐stimulated phosphoprotein (VASP) levels (c) in venous blood at different time points over the observation period compared with baseline levels. *P < 0.05 for changes from baseline to 2 hours, from baseline to 24 hours, from 2 to 24 hours, and between treatment groups. n.s., nonsignificant; PRI, platelet reactivity index; U, units.

• 

  Figure 2. Boxplot of the effects of ticagrelor combined with aspirin and ticagrelor combined with placebo on thromboxane B2 (TxB2) levels in venous blood at baseline and 24 hours after study treatment. *P < 0.05 for changes from baseline to 24 hours and between treatment groups. n.s., nonsignificant.

• 

  Figure 3. Boxplots of the effects of ticagrelor combined with aspirin and ticagrelor combined with placebo on prothrombin fragment 1.2 (f1.2) (a) and d‐Dimer (b) levels in venous blood at different time points over the observation period compared with baseline levels. *P < 0.05 for changes from baseline to 2 hours, from baseline to 24 hours, from 2 to 24 hours, and between treatment groups. n.s., nonsignificant.